Loading chat...
SD HB1099
Bill
Status
Passed
3/10/2026
Primary Sponsor
Tom Pischke
Click for details
AI Summary
- Reclassifies FDA-approved crystalline polymorph psilocybin drug products from Schedule I to Schedule IV controlled substances in South Dakota
- Amends § 34-20B-14 to add an exception for FDA-approved psilocybin formulations from the Schedule I hallucinogenic substances list
- Amends § 34-20B-25 to add FDA-approved crystalline polymorph psilocybin as item (65) on the Schedule IV controlled substances list
- Psilocybin in non-FDA-approved forms remains a Schedule I substance under state law
- Schedule IV classification places these psilocybin products in the same regulatory category as benzodiazepines, tramadol, and other prescription medications with lower abuse potential
Legislative Description
Reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.
Controlled Substances
Last Action
Signed by the Governor on March 10, 2026 H.J. 547
3/10/2026
Committee Referrals
Health and Human Services2/10/2026
Health and Human Services1/21/2026
Full Bill Text
No bill text available